Pacific Biosciences of California, Inc. (PACB) Sentiment Analysis

Pacific Biosciences of California, Inc. (PACB) has an ST Score of 39.8 (C), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.

Analysts rate PACB a Buy, with a price target of $1.18 (-25.3% vs the current price). Our ST Score grades it C (39.8/100). The ST Score is a data-driven signal, not a recommendation.

Valuation A-, Profitability D+, Financial Strength B-, Momentum A-, Growth C-, Forecast C, Sentiment F.

Pacific Biosciences of California, Inc. (PACB) earns a valuation grade of A-, measured against Medical - Devices peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.

Pacific Biosciences of California, Inc. (PACB) earns a growth grade of C-, measured against Medical - Devices peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.

Pacific Biosciences of California, Inc. (PACB) earns a profitability grade of D+, measured against Medical - Devices peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.

Pacific Biosciences of California, Inc. (PACB) earns a financial strength grade of B-, measured against Medical - Devices peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.

The average analyst price target for Pacific Biosciences of California, Inc. (PACB) is $1.18 from 18 analysts, which is -25.3% versus the recent price of $1.58.

Pacific Biosciences of California, Inc. (PACB) has a Piotroski F-Score of 2 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.